Company news

Stoke Therapeutics, Inc. news in 2022

Stoke Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting

December 1, 2022

Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting

November 28, 2022

Stoke Therapeutics to Host Webinar and Conference Call to Present Interim Data from the Phase 1/2a Studies of STK-001 in Children and Adolescents with Dravet Syndrome

November 9, 2022

Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic Atrophy (ADOA)

August 24, 2022

Stoke Therapeutics to Present at the 2022 Jefferies Healthcare Conference

May 31, 2022

Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002

May 1, 2022

Stoke Therapeutics to Present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

April 6, 2022

Stoke Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

April 4, 2022

Stoke Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

March 9, 2022

Stoke Therapeutics to Participate in the Cowen 42nd Annual Health Care Conference

February 27, 2022

Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases

January 9, 2022

Stoke Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 3, 2022

Calls in 2022

Decks in 2022